Roberts Alison, Dart Julie, Lloyd Selena, Bebbington Keely, Fairchild Janice M, Ambler Geoffrey R, Cameron Fergus J, Davis Elizabeth A, Jones Timothy W, Abraham Mary B
Children's Diabetes Centre Telethon Kids Institute The University of Western Australia, Perth, Australia.
Department of Endocrinology and Diabetes Perth Children's Hospital, Perth, Australia.
Pediatr Diabetes. 2024 Sep 3;2024:6260002. doi: 10.1155/2024/6260002. eCollection 2024.
Advanced hybrid closed-loop (AHCL) therapy improves glycemia. However, it is not known if there is an improvement in overall outcomes with AHCL for youth with type 1 diabetes (T1D) at high risk of diabetes-related complications. The study aimed to capture the experiences of youth with suboptimal glycemic control when commencing AHCL therapy in a clinical trial setting.
This was a singlecenter substudy of a multicenter 6-month randomized clinical trial. Youth between 12 and 25 years of age on insulin pump therapy with HbA1c > 8.5% (> 69 mmol/mol) who commenced AHCL therapy with Medtronic MiniMed™ system were invited to participate in a semistructured interview after 6 months of AHCL. Open-ended questions were used to explore the participants' lived experience of AHCL in improving their glucose levels and its impact on diabetes management and well-being. The interviews were audiorecorded, transcribed, and analyzed using thematic analysis.
Ten youth with T1D with a mean (SD) age of 17.4 (2.9) years, diabetes duration 10.7 (4.8) years, HbA1c 10.2 (0.8)%, or 87 (9.5) mmol/mol at enrollment participated in the interview. Three main themes were identified: (1) improved glycemia despite not using closed loop to its full potential; (2) persistent diabetes burden; and (3) a need for increased psychosocial and clinical support. Although improved glycemia was noted with AHCL therapy, participants reported ongoing motivation issues and used the system suboptimally. They continued to experience distress with overall diabetes management and acknowledged the need for ongoing support from family and health professionals.
All participants reported overall satisfaction with improved glucose levels, however, the persistent diabetes burden impacted their ability to use AHCL optimally. The need for ongoing monitoring with support and interventions to enhance psychological care remains vital for youth with suboptimal diabetes management.
先进的混合闭环(AHCL)疗法可改善血糖水平。然而,对于有糖尿病相关并发症高风险的1型糖尿病(T1D)青少年而言,AHCL是否能改善总体预后尚不清楚。该研究旨在了解在临床试验环境中开始AHCL治疗时血糖控制不佳的青少年的经历。
这是一项多中心6个月随机临床试验的单中心子研究。邀请年龄在12至25岁、接受胰岛素泵治疗且糖化血红蛋白(HbA1c)>8.5%(>69 mmol/mol)并开始使用美敦力MiniMed™系统进行AHCL治疗的青少年,在AHCL治疗6个月后参加半结构化访谈。采用开放式问题来探究参与者在AHCL改善血糖水平方面的生活体验及其对糖尿病管理和幸福感的影响。访谈进行了录音、转录,并采用主题分析法进行分析。
10名患有T1D的青少年参与了访谈,他们的平均(标准差)年龄为17.4(2.9)岁,糖尿病病程为10.7(4.8)年,入组时HbA1c为10.2(0.8)%,即87(9.5)mmol/mol。确定了三个主要主题:(1)尽管未充分发挥闭环功能,但血糖仍有所改善;(2)持续存在的糖尿病负担;(3)需要增加心理社会和临床支持。尽管AHCL治疗使血糖得到改善,但参与者报告称仍存在动机问题,且对系统的使用未达最佳状态。他们在整体糖尿病管理方面仍感到困扰,并承认需要家人和健康专业人员持续提供支持。
所有参与者均报告对血糖水平的改善总体满意,然而,持续存在的糖尿病负担影响了他们最佳使用AHCL的能力。对于糖尿病管理欠佳的青少年,持续进行监测并提供支持和干预以加强心理护理仍然至关重要。